Literature DB >> 24817569

Breakthrough pain in elderly patients with cancer: treatment options.

Sophie Pautex1, Nicole Vogt-Ferrier, Gilbert B Zulian.   

Abstract

The prevalence of pain is high in the elderly and increases with the occurrence of cancer. Pain treatment is challenging because of age-related factors such as co-morbidities, and over half of the patients with cancer pain experience transient exacerbation of pain that is known as breakthrough pain (BTP). As with background pain, BTP should be properly assessed before being treated. The first step to be taken is optimizing around-the-clock analgesia with expert titration of the painkiller. Rescue medication should then be provided as per the requested need, while at the same time preventing identified potential precipitating factors. In the elderly, starting treatment with a lower dose of analgesics may be justified because of age-related physiological changes such as decreased hepatic and renal function. Whenever possible, oral medication should be provided prior to a painful maneuver. In the case of unpredictable BTP, immediate rescue medication is mandatory and the subcutaneous route is preferred unless patient-controlled analgesia via continuous drug infusion is available. Recently, transmucosal preparations have appeared in the medical armamentarium but it is not yet known whether they represent a truly efficient alternative, although their rapid onset of activity is already well recognized. Adjuvant analgesics, topical analgesics, anesthetic techniques and interventional techniques are all valid methods to help in the difficult management of pain and BTP in elderly patients with cancer. However, none has reached a satisfying scientific level of evidence as to nowadays make the development of undisputed best practice guidelines possible. Further research is therefore on the agenda.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24817569     DOI: 10.1007/s40266-014-0181-5

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  55 in total

Review 1.  The management of persistent pain in older persons.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2002-06       Impact factor: 5.562

2.  Morphine remains gold standard in breakthrough cancer pain.

Authors:  Vicente Ruiz-Garcia; Eduardo Lopez-Briz
Journal:  BMJ       Date:  2008-12-24

3.  Undertreatment of cancer pain in elderly patients.

Authors:  C S Cleeland
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272

4.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Authors:  P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

Review 5.  Practice guidelines for transdermal opioids in malignant pain.

Authors:  Tracy L Skaer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Pain assessment strategies in older patients.

Authors:  Keela Herr
Journal:  J Pain       Date:  2011-03       Impact factor: 5.820

7.  Breakthrough cancer pain: an observational study of 1000 European oncology patients.

Authors:  Andrew Davies; Alison Buchanan; Giovambattista Zeppetella; Josep Porta-Sales; Rudolf Likar; Wolfgang Weismayr; Ondrej Slama; Tarja Korhonen; Marilene Filbet; Philippe Poulain; Kyriaki Mystakidou; Alexandros Ardavanis; Tony O'Brien; Pauline Wilkinson; Augusto Caraceni; Furio Zucco; Wouter Zuurmond; Steen Andersen; Anette Damkier; Tove Vejlgaard; Friedemann Nauck; Lukas Radbruch; Karl-Fredrik Sjolund; Mariann Stenberg
Journal:  J Pain Symptom Manage       Date:  2013-03-22       Impact factor: 3.612

Review 8.  The pharmacoeconomics of breakthrough cancer pain.

Authors:  Kuan-Ling Kuo; Surasak Saokaew; David D Stenehjem
Journal:  J Pain Palliat Care Pharmacother       Date:  2013-05-20

9.  A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.

Authors:  Roelien H Enting; Wendy H Oldenmenger; Carin C D van der Rijt; Erik B Wilms; Erna J Elfrink; Ineke Elswijk; Peter A E Sillevis Smitt
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

10.  Age, pain intensity, and opioid dose in patients with advanced cancer.

Authors:  A Viganó; E Bruera; M E Suarez-Almazor
Journal:  Cancer       Date:  1998-09-15       Impact factor: 6.860

View more
  6 in total

Review 1.  Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.

Authors:  Paolo Bossi; Yolanda Escobar; Federico Pea
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-26

2.  Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.

Authors:  Jordi Guitart; María Isabel Vargas; Vicente De Sanctis; Jordi Folch; Rafael Salazar; José Fuentes; Joan Coma; Julia Ferreras; Jordi Moya; Albert Tomás; Pere Estivill; Francisco Rodelas; Antonio Javier Jiménez; Almudena Sanz
Journal:  Drugs R D       Date:  2018-06

3.  Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.

Authors:  Jordi Guitart; María Isabel Vargas; Vicente De Sanctis; Jordi Folch; Rafael Salazar; José Fuentes; Joan Coma; Julia Ferreras; Jordi Moya; Albert Tomás; Pere Estivill; Francisco Rodelas; Antonio Javier Jiménez; Almudena Sanz
Journal:  Drugs R D       Date:  2017-09

4.  Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.

Authors:  Jordi Guitart; María Isabel Vargas; Vicente De Sanctis; Jordi Folch; Rafael Salazar; José Fuentes; Joan Coma; Julia Ferreras; Jordi Moya; Albert Tomás; Pere Estivill; Francisco Rodelas; Antonio Javier Jiménez; Almudena Sanz
Journal:  Drugs R D       Date:  2019-09

Review 5.  Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.

Authors:  Jenny K W Lam; Chucky C K Cheung; Michael Y T Chow; Emily Harrop; Susie Lapwood; Stephen I G Barclay; Ian C K Wong
Journal:  Adv Drug Deliv Rev       Date:  2020-11-01       Impact factor: 15.470

6.  Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.

Authors:  Masoud Hashemi; Alireza Zali; Ebrahim Golmakani; Mohammad Hossein Delshad; Mahdi Shadnoush; Mohammad-Esmaeil Akbari
Journal:  Daru       Date:  2021-01-21       Impact factor: 3.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.